Aastrom Biosciences, Inc. develops patient-specific cell products for treating severe, chronic ischemic cardiovascular diseases. The company is developing ixmyelocel-T, a multicellular therapy expanded from a patient’s own bone marrow and delivered directly to damaged tissues. Ixmyelocel-T is in late-stage clinical development, including a Phase III clinical program to study patients with critical limb ischemia and a Phase IIb clinical trial in patients with ischemic dilated cardiomyopathy. For more information, visit the company’s website at www.aastrom.com.